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Abstract 
 
Hepatitis B virus (HBV) infection, one of the major health priorities, accounts approximately for 350 million chron-
ic cases and a global total of 33 million people were living with human immunodeficiency virus (HIV) in the world. 
Co-infection with HIV and the HBV presents a significant challenge to health care providers, with different preva-
lence rates in different parts of the world. It is important to screen all HIV infected individuals for HBV infection 
and reverse. Infection with HBV becomes more violent in patients co-infected with human immunodeficiency 
syndrome. HIV/HBV co-infected individuals are at increased risk of chronic hepatitis, cirrhosis, and hepatocellular 
carcinoma, and of experiencing HAART toxicity. In this review, the latest statistics on epidemiology of HIV, HBV 
and their co-infection has been presented along with prominent characteristics of HBV. Transmission routes 
which are the common between HBV and HIV are described and the most important ones are described accord-
ing to the regional and age features. Also, there is a series of actions being performed once HBV infections occur 
to prevent HIV or to diagnose if the HBV-infected individuals are also infected with HIV. As in treatment case, 
some of the frequent treatment methods including applying interferon and using nucleoside and nucleotide ana-
logues have been discussed. Finally, we would explain the new recommendations for treating patients who were 
co-infected with HBV and HIV, including staging HBV and HIV treatment, based on the stage of each disease.  It 
also outlines the optimal treatment options, whether the patient is treated for HBV first, HIV first, or HIV and HBV 
together. 
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Latest Courses in Epidemiology 
 
Hepatitis B, one of the major health priorities, ac-
counts approximately for 350 million chronic cases 
out of 2 billion people infected worldwide.
1 An esti-
mated 600,000 people die each year because of the 
acute or chronic consequences of hepatitis B. Human 
immunodeficiency virus (HIV)  is one of the other 
viruses in charge of infectious diseases. A global total 
of 33 million (30.6–36.1 million) people were living 
with HIV from which 2.7 million (2.2–3.2 million) 
individuals were newly infected in the late 2008 and 
2.0 million (1.8–2.3 million) died of AIDS-related 
illnesses in 2007 (Table 1).
2 Infection with HBV as 
well as HIV infection is one of the major concerns 
globally. Co-infection with the HIV and the hepatitis 
B virus (HBV) presents a significant challenge to 
health care providers, with different prevalence rates 
in different parts of the world and in average affecting 
approximately 10% of persons with HIV infection.
3 
HBV and HIV share the common mode of transmis-
sion; thus co-infection of these two viruses occurs 
frequently.
4,5 Despite the high rate of co-infection, the 
correlation between HBV and HIV mostly depends 
on the affected community as well as transmission 
route. In Iran as an instance, HBV alone has been 
transmitted vertically and most HBV affected indi-
viduals were nevertheless HIV negative.
6,7 Routes of 
transmission can be characterized by the geographical 
origin of infected patients as in low HBV prevalence 
≤2% HBsAg - in USA, Western Europe, Australia, 
and New Zealand which is mostly caused by drug 
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injection and unprotected sex between adults. In this 
case, there is a co-infection rate of 5-10% which is  
10 times higher than general population. Average 
prevalence of 2-7% HBsAg- has been reported in Ja-
pan, Middle East, Central America, and Latin Ameri-
ca. Finally, high HBV endemicity of 8-15% HBsAg 
exists in Sub-Saharan Africa, South East Asia, and 
China. Perinatal transmission, close contact with 
households, and medical or cultural procedures (scari-
fication and tattoos in Africa) are the most common 
ways of viral spread in second group in which 10-
20% corresponds for the co-infection.
8,9  
Moreover in Iran, the prevalence of HBsAg has 
differed through the time and after mass vaccination 
in following years, the number of HBsAg positive 
individuals started to decrease. Recent studies have 
shown a remarkable decline where the prevalence rate 
of HBV was 2.14%  or generally 1.5 million people 
all over the country.
10 Hajiani et al. as well as 
Nokhodian et al. have provided epidemiological data 
which shows different prevalence ratios in various 
areas of Iran fluctuating from 1.7% in Fars Province 
to 5.0% in Sistan and Baluchestan Province.
7,11 A re-
cent study by Seyed Alinaghi in 2010 illustrates that 
3% of general population were infected with HBV 
before the year 1993; it reduced to 1.5-2% in current 
years, though, mostly because of the medical cares 
performed by health providers in Iran.
12 Around 40 
million people are worldwide infected with HIV.
13 
After introduction of highly active antiretroviral ther-
apy (HAART) has led to a decline in death rate from 
AIDS-related causes and  liver disease still appears to 
be one of the primary causes of morbidity and mortal-
ity, though.
14,15 mostly the parts of the world with a 
high rate of one infection overlap with high preva-
lence of the other one, that is, infection with one of 
the viruses is mostly followed by the other one. In 
case of HBV/HIV co-infection, biological signs of 
prior HBV infection have been seen in 90% of HIV-
infected individuals (defined by the presence of se-
rum anti-HBc Ab) and 5–15% showed chronic infec-
tion (defined by the presence of serum HBsAg) all 
around the world.
16 HBV incidence fluctuated mark-
edly among different HIV-infected populations, but 
Table 1: HIV and AIDS prevalence in various regions, a comparison between years 2001 and 2008.
19 
 Year  Adults  and  chil-
dren living with 
HIV 
Adults and chil-
dren newly in-
fected with HIV
Adult prev-
alence (%) 
Adult and child 
deaths due to 
AIDS 
High preva-
lence (8-15%) 
Sub-
Saharan 
Africa 
2008 22.4  million 
(20.8-24.01 million) 
1.9 million 
(1.6-2.2 million) 
5.2 
(4.9-5.4) 
1.4 
(1.1-1.7) 
2001 19.7  million 
(18.3-21.2 million) 
2.3 million 
(2.0-2.5 million) 
5.8 
(5.5-6.0) 
1.4 
(1.2-1.7) 
South and 
South-East 
Asia 
2008 3.8  million 
(3.4-4.3 million) 
280000 
(240000-320000) 
0.3 
(0.2-0.3) 
270000 
(220000-310000) 
2001 4.0  million 
(3.5-4.5 million) 
310000 
(270000-350000) 
0.3 
(<0.3-0.4) 
260000 
(210000-320000) 
Intermediate 
prevalence 
(2-7%) 
Middle 
East and 
North Afri-
ca 
2008 310000 
(250000-380000) 
35000 
(24000-46000) 
0.2 
(<0.02-0.3) 
20000 
(15000-25000) 
2001 200000 
(150000-250000) 
30000 
(24000-46000) 
0.2 
(0.1-0.2) 
11000 
(7800-14000) 
Latin 
America 
2008 2.0  million 
(1.8-2.2 million) 
170000 
(150000-200000) 
0.6 
(0.5-0.6) 
77000 
(66000-89000) 
2001 1.6  million 
(1.5-1.8 million) 
150000 
(140000-170000) 
0.5 
(<0.5-0.6) 
66000 
(56000-77000) 
Low preva-
lence (<2%) 
Western 
and Cen-
tral Europe 
2008 850000 
(710000-970000) 
30000 
(23000-35000) 
0.3 
(0.2-0.3) 
13000 
(10000-15000) 
2001 660000 
(580000-760000) 
40000 
(31000-47000)  
0.2 
(<0.2-0.3) 
7900 
(6500-9700) 
North 
America 
2008 1.4  million 
(1.2-1.6 million) 
55000 
(36000-61000) 
0.6 
(0.5-0.7) 
25000 
(20000-31000) 
2001 1.2  million 
(1.1-1.4 million) 
52000 
(42000-60000) 
0.6 
(0.5-0.7) 
19000 
(16000-23000) Epidemiology of HIV/HBV co-infections 
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geographical location established different rates. In 
areas with low HBV endemicity, such as the United 
States, Australia, and Europe, HBV and HIV usually 
happened in adulthood either sexually or through   
percutaneous transmission. Infection with HBV often 
follows HIV because HBV is nearly 100-fold more 
likely to be transmitted than HIV. The prevalence of 
HBV co-infection in such low endemicity areas is 5-
7% of HIV-infected individuals but it is affected by 
route of infection. The highest frequency of co-
infection is because of MSM (men who have sex with 
men), ranging from 9-17%, and the lowest was from 
heterosexual transmission.
17 Whereas in countries 
with intermediate and high HBV endemicity, the 
main routes of HBV transmission were perinatal or in 
early childhood; so HBV infection usually preceded 
HIV infection by decades. In these countries, most 
studies suggested that HBV co-infection prevalence 
was 10- 20%, but some showed as low as 6%.
18  
Nowadays, around 1/3 of people in the world had 
a contact history with HBV infection presented with 
isolated anti-HBcAb during their lives. Among these, 
350 million remained infected chronically and be-
came carriers of the virus. Three quarters of the 
world’s population live in areas where there are high 
levels of infection.
19 There is a new entity in co-
infection of HBV/HIV that the HBs Ag is negative 
and occult HBV persists.
20,21 The prevalence of OBI 
in HIV-positive patients varies considerably from 0% 
to 89.5% in different geographical regions.
21 
 
 
Virological Features 
 
Classification and Structure 
HBV, a prototype member of the Hepadnaviridae 
(hepatotropic DNA virus) family, is one of the 
Hepadnaviruses which strongly appeals to infect liver 
cells, but hepadnaviral DNA can be traced in pancre-
as, kidney, and mononuclear cells, as well.
22,23 HBV 
virions are particles with double shells, 40 to 42 nm 
thick with an outer lipoprotein envelope. The enve-
lope has three envelope glycoproteins (or surface an-
tigens) related to each other. The viral nucleocapsid 
which is also called core exists within the envelope. 
Viral genome, a relaxed-circular, partially duplex 
DNA containing 3.2 kb, and a polymerase responsible 
for the synthesis of viral DNA in infected cells are 
included in the core. HBV virus seems to have multi-
ple viral genotypes, according to the data acquired 
from DNA sequencing of many isolates of HBV, each 
of which with a characteristic geographic distribu-
tion.
24-26 Other than virions, cells infected with HBV 
produce two different subviral lipoprotein particles of 
spheres and filamentous forms of about 20 nm. Enve-
lope glycoproteins and host-derived lipids are the on-
ly parts HBsAg particles and they are usually signifi-
cantly more than virions in number (1000:1 to 
10,000:1).
25 
 
Pathogenesis of Hepatitis B 
The HBV replication cycle is not directly cytotox-
ic to cells, as in, many HBV carriers show no symp-
toms and have minimal liver injury, however intrahe-
patic replication of the virus continues extensively. 
Therefore, immune responses to viral antigens ex-
pressed by infected hepatocytes are the main signs of 
hepatocellular injury. Clinical observations also 
showed that patients who suffered from immune de-
fects and were infected with HBV often had mild 
acute liver injury but were major chronic carriers.
27,28 
The immune responses to HBV and their role in the 
hepatitis B pathogenesis are still not completely un-
derstood. Several clinical studies showed that in 
acute, self-limited hepatitis B, strong T-cell responses 
against many HBV antigens were proven to exist in 
the peripheral blood, including both major-
histocompatibility-complex (MHC) class II, CD4+ 
helper T cells and MHC class I, CD8+ cytotoxic T 
lymphocytes. The antiviral cytotoxic T-lymphocyte 
response which is against multiple epitopes within the 
HBV core, polymerase, and envelope proteins, and 
also strong helper T-cell - against C and P proteins- 
occur in acute infection. By contrast, in chronic carri-
ers of HBV, such virus-specific T-cell responses are 
greatly reduced, at least as examined in cells obtained 
from peripheral blood.
29 Following the introduction 
of highly active antiretroviral therapy (HAART), liver 
disease is now the major cause of non-AIDS-related 
deaths in HIV-1-infected patients.
30-32 Progression to 
cirrhosis seems to be more rapid and more common, 
and liver-related mortality is higher, in HIV/HBV co-
infection than with either infection alone.
33 
 
 
Natural History and Transmission Routes 
 
Hepatitis B Virus 
Percutaneous and mucous membrane exposures to 
infectious blood and body fluids containing blood are 
the main routes of HBV transmission.
34 Percutaneous 
exposure includes blood or blood products transfu-Ranjbar et al. 
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sion, using contaminated equipment in therapeutic 
injections and other health-care related practices, in-
jectable drug use, and needle sticks or other injuries 
from sharp instruments occurred by hospital staff.
35,36 
Perinatal and sexual exposures to HBV are two other 
modes of transmission which are extremely efficient. 
HBV can also spread among household through con-
tacts with a chronically infected person.
37,38 Moreo-
ver, tattooing and acupuncture have been in charge of 
some occasional outbreaks.
36 Chronic HBV infection 
is considered as two distinct phases: HBeAg positive 
and HBeAg negative.
39 In most cases, transmissions 
result from non-compliance with aseptic techniques 
and recommended infection control procedures that 
were designed to prevent post-practice infections due 
to cross-contamination of medical equipment and de-
vices. In developing countries, donor testing for 
HBsAg is not common and, unsafe therapeutic injec-
tion practices, including inadequately sterilized nee-
dles and medical instruments, the reuse of disposable 
needles and syringes, and contamination of multiple 
dose medication vials are still responsible for trans-
mission which has made it a significant problem.
40-43 
There are also some cases of occult HBV infec-
tions which are described as the existence of HBV 
DNA without detectable HBsAg. Antibodies against 
hepatitis B core antigen (anti-HBc) are often the only 
serum markers in mono-infected patients with occult 
HBV. So in cases with high risk of hepatitis B where 
HBsAg is negative, it is needed to check anti-HBc 
level. The presence of anti-HBc is rarely coupled with 
occult infection in HIV-uninfected patients, though. 
Thus, HBV DNA should be measured.
44 
 
Co-Infection with HIV 
HBV and HIV have similar characteristics such as 
transmission modes; using a reverse transcriptase en-
zyme in replication; the tendency to develop chronic 
infections, which are often difficult to treat; and final-
ly, an immense capacity of mutation in their genome, 
causing rapid emergence of mutant strains, some of 
which are resistant to widely used anti-viral agents. In 
addition, both viral genomes can integrate within the 
host genome, a process which is obligatory for the 
life cycle of HIV, but not for HBV.
45 
Among the estimated 40 million persons infected 
with HIV worldwide, an estimated 2–4 million are 
chronically infected with HBV.
31 In general, HBV 
tends to be more aggressive in HIV-positive individu-
als than in mono-infected individuals, with higher 
HBV carrier rates, higher levels of HBV viremia, 
more frequent episodes of activation, and faster pro-
gression to cirrhosis.
46,47 Several factors are effective 
in estimating these co-infection rates, such as geo-
graphic differences in the incidence of chronic infec-
tion by age, the efficiency of exposures which is di-
rectly responsible for most transmissions, and the 
prevalence of persons at high risk for infection.
36 Co-
infection with HBV and HIV follows a different 
course everywhere in the world. For example, neona-
tal or childhood infection, with either vertical or hori-
zontal transmission is the most common route of 
transmission in Africa and Asia after birth.  In parts 
of Africa, ritual scarification seems to have a major 
role in the adolescent transmission of HBV.
48,49 (ritual 
scarification is known as the practice of making small 
incisions in the skin of adolescents and rubbing black 
ash in the wounds to form scars; the instruments be-
ing used for cutting are not sterilized between rituals). 
Co-infection with HIV alters the natural history of 
chronic hepatitis B. Increasing serum HBV DNA 
concentrations, decline in liver enzyme levels and 
developing faster liver cirrhosis, particularly in those 
with low CD4 counts, are some of the symptoms of 
this phenomenon (Table 2). The most prominent issue 
among all these negative consequences is the faster 
progression of HBV-related liver disease. Cirrhosis 
has been more commonly reported in HIV-HBV co-
infection individuals despite lower alanine ami-
notransferase (ALT) levels than in HBV mono-
infection, and it may be related to lower CD4+ T cell 
counts.
50,51 Co-infection of HBV with HIV changes 
the natural history of HBV infection. HIV-HBV co-
infected patients seroconvert from HBV e (precore) 
antigen (HBeAg) to HBV e antibody less frequently 
and have higher HBV DNA levels but lower levels of 
alanine aminotransferase (ALT). HBeAg is an accessory 
protein of HBV and is not necessary for viral replica-
tion or infection. Most studies on natural history of 
HIV- HBV co-infection until now have principally 
Table 2: Effects of HIV on the Natural History of Adult-Acquired HBV Infection.
50
Effects Comment
Increase risk for developing chronic HBV infection  Studies in men who have sex with men. Lower CD4+ 
Decreased rate of HBeAg clearance  T-cell count with higher risk of chronicity 
Increased HBV replication  Demonstrated with higher HBV DNA levels 
Decreased inflammatory response to chronic hepatitis B  Lower ALT levels 
Increased liver disease progression  More cirrhosis and higher liver-related mortality 
 Epidemiology of HIV/HBV co-infections 
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focused on non-Asian patients with HBeAg-
positive.
50,52 
 
Diagnosis 
Hepatitis B virus is a dynamic virus and its co-
infection with HIV makes the diagnosis process sig-
nificantly difficult. However, proper diagnosis and 
monitoring of co-infection of hepatitis B and HIV, 
along with complete understanding of the mecha-
nisms of drug resistance, will allow researchers and 
clinicians to manage co-infection cases more effi-
ciently. In general, there is a series of actions for the 
diagnosis or even prevention of co-infections which 
are mostly recommended to be accomplished in cases 
of new HIV infections. First, all individuals diag-
nosed with HIV recently, should be examined for 
hepatitis B surface antigen (HBsAg) and anti-HBs. 
Positive HBsAg expresses HBV co-infection. For 
HBsAg positive patients, HBeAg, anti-HBe and HBV 
DNA should be tested, otherwise it is recommended 
to apply HBV vaccination. In addition to a complete 
history and physical examinations, newly HIV infect-
ed patients’ bloods should be screened for complete 
blood pictures, clotting profiles including prothrom-
bin time, international normalized ratio (INR), alpha-
fetoprotein (AFP) and tests on liver and renal func-
tions. Performing a baseline hepatic ultrasound is the 
next step.
46 Finally, to screen the condition of the liver, 
it is highly recommended to assess fibrosis using liver 
biopsy in individuals suspicious of having HBV/HIV 
co-infection. However, sampling variations, inter-
observers’ variability and the risk of complications 
have considerably limited the liver biopsy.
53,54 
 
Treatment 
Significance of HBV/HIV co-infection has led to 
extensive progress in prescription of HBV in HIV-co-
infected individuals. Liver injuries are also more 
common in these patients for whom treatment options 
have widely developed. 
 
Interferon 
In HBV monotherapy, suppression of viral replica-
tion is the aim of therapy. Interferon in form of stand-
ard or pegylated may be a proper treatment for chron-
ic HBV infection in patients who have not yet started 
highly active antiretroviral therapy (HAART) for 
their HIV.
59 Interferon is limited to patients who tend 
to seroconvert; in other words, the female patients 
with high ALT levels, low HBV DNA levels, and 
positive HBeAg status in whom liver decompensation 
has not occurred yet.
55,56 It is also a major concern 
that interferon therapy is just effective with HBV in-
fection not HIV.
55 It is known that alpha interferon 
which is available in pegylated form is the most ef-
fective therapy for HBsAg positive patients. Levy and 
Grant have stated that using IFN-α once-weekly for 
about 16 weeks can be influential in treatment trend. 
Flulike symptoms, psychiatric effects, bone marrow 
suppression and thyroid dysfunction are some factors 
which limit the interferon activity.
57 
In a study performed by Matthews, patients re-
ceiving interferon therapy were shown to get signifi-
cantly more improved with pegylated interferon com-
pared to nucleosides and nucleotide analogues alone. 
After 48 of therapy in these patients, HBeAg sero-
conversion, HBV DNA suppression and ALT normal-
ization became better.
58 
 
 
Nucleoside and Nucleotide Analogues 
 
Entecavir, a partial inhibitor of HIV replication along 
with lamivudine are applied to induce the YMDD 
mutation in HIV polymerase which is an indication of 
resistance to therapy. Tenofovir is another option to 
be chosen for resistance mutations in HIV polymer-
ase.
55 In coinfected patients who develop resistance to 
lamivudine, the recommended treatment is tenofovir 
plus entecavir (because there is no cross-reactivity 
between these two agents), tenofovir plus lamivudine 
or emtricitabine. Some evidences suggest that 
entecavir resistance is inclined by lamivudine re-
sistance, but the same studies were performed in pa-
tients with very high baseline viral loads; the effi-
ciency of entecavir in patients who had low baseline 
viral loads is unknown. It is assumed that when 
entecavir is used along with another potent nucleoside 
analogue in coinfected patients, the sensitivity of 
HBV would be more durable than when entecavir is 
used alone as monotherapy.
59 
 
 
Treating HIV and HBV Infections Concurrently 
 
To initiate the treatment in co-infected patients, some 
factors such as combination antiretroviral therapy for 
HIV infection, the severity of liver disease, probabil-
ity of various reactions, and potential adverse events 
should be taken into account.
57 When treatment is 
necessary for both HBV and HIV infections, HAART 
is needed for HIV. Using standard therapy for HIV, it Ranjbar et al. 
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is the main treatment strategy in co-infection whereas 
two effective agents should be selected against HBV 
infection. Because antiviral resistance is a probability 
in treatment, choosing active agents seems complicat-
ed, that is the choices for treatment of HBV infection 
are limited by resistance to HIV therapy. The first 
aim of therapy is to decrease the amount of HBV 
DNA to an undetectable level; so using less potent 
agents is not an option. The most potent agent such as 
tenofovir plus lamivudine or tenofovir plus emtricita-
bine is recommended as the best choice (Figure 1).
55,56 
In a study performed by GERMIVIC Study Group, 
Piroth  et al. reported that lamivudine monotherapy 
was a very common and a first-line treatment. Other 
treatment methods included in their study were 
tenofovir along with lamivudine or emtricitabine, and 
tenofovir alone.
60 One of the important implications 
in the treatment of HBV-HIV co-infection was that 
the dosages of different medications being applied 
should be adjusted to HBV condition. 
 
Conclusion 
 
According to the data acquired from different sources 
and authorities, it is comprehended that HBV/HIV 
co-infection rate might grow if appropriate control-
ling mechanisms are not considered. Epidemiological 
investigations are needed to be performed, so that 
atypical transmission routes and high risk locations 
and environment would be identified. Researches in 
behavior are also necessary in case of further under-
standing of failures and not effective treatments. 
Moreover, observation systems seem necessary to 
monitor infection patterns to target high prevalence 
regions. To define upper limit of HBV DNA level, 
clinical studies are needed to be performed for the on-
set of treatment in both liver disease and co-infection. 
Finally, recent research showed expanded access to 
proper treatment methods that can help to reduce the 
morbidity and mortality rate in HIV- or HBV- infec-
tions and also in co-infections, mostly by lowering the 
viral load among individuals and communities. 
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